MOTS-c has an unusual origin story among research peptides: it isn't encoded in nuclear DNA at all. It's produced from a small open reading frame hidden inside the mitochondrial 12S rRNA gene — a discovery that reframed mitochondria as more than an energy factory.
What Is MOTS-c?
MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA rather than the cell nucleus, giving it a direct structural link to cellular energy status.
Mechanism of Action
The foundational 2015 Cell Metabolism study found MOTS-c inhibits the folate cycle and its linked de novo purine biosynthesis pathway, which drives a greater than 20-fold increase in endogenous AICAR — a natural AMPK activator. That AMPK activation upregulates GLUT4 expression in skeletal muscle, improving glucose uptake. In treated mice, this prevented high-fat-diet-induced weight gain and insulin resistance, and separately prevented age-dependent insulin resistance.
What the Preclinical Research Shows
- AMPK-pathway activation via a >20-fold increase in endogenous AICAR
- GLUT4 upregulation in skeletal muscle, improving glucose uptake
- Prevention of high-fat-diet-induced obesity and insulin resistance in mouse models
- Prevention of age-dependent insulin resistance in aging mouse models
- Reduced sphingolipid, monoacylglycerol, and dicarboxylate metabolism pathways — pathways normally elevated in obesity and type 2 diabetes
MOTS-c's mechanism is well-characterized at the molecular and animal-model level. Human trial data remains early — the metabolic effects described above have not been established in human clinical trials.
Regulatory Status
MOTS-c was one of seven peptides FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed on July 23–24, 2026 for the Section 503A Bulk Drug Substances List — the same meeting that reviewed BPC-157, TB-500, and Epitalon. FDA staff recommended against all seven; the committee voted narrowly to recommend MOTS-c anyway, one of six peptides the panel backed — only Emideltide was voted down.
This is a non-binding recommendation, not an approval. Formal rulemaking, if FDA pursues it, could take until 2027 or 2028. MOTS-c remains not FDA-approved for any human use today.
Where to Source MOTS-c for Research
For legitimate research applications, purity and accurate dosing are critical. We only list vendors who provide third-party HPLC testing and batch-specific Certificates of Analysis.
View the MOTS-c product page →Frequently Asked Questions
How is MOTS-c different from other metabolic peptides on this site?
It's encoded directly in mitochondrial DNA rather than the cell nucleus — a structurally distinct origin from peptides like GHK-Cu or the GH secretagogues. Its studied mechanism (AMPK activation via AICAR) is also distinct from GLP-1 appetite-suppression pathways.
Is MOTS-c FDA-approved?
No. A July 2026 FDA advisory committee voted to recommend it for the compounding-eligible substances list, over FDA staff's own objection, but that's a non-binding recommendation, not an approval.
References
1. Lee C, et al. "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance." Cell Metabolism, 2015. cell.com
2. "MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism." PubMed. pubmed.ncbi.nlm.nih.gov
3. "MOTS-c Functionally Prevents Metabolic Disorders." PubMed. pubmed.ncbi.nlm.nih.gov
4. Stone W. "FDA panel supports broadening access to peptides popular on the gray market." NPR, July 23–24, 2026. npr.org
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. All compounds are for research use only.